0.42
+0.0237(+5.98%)
Currency In USD
| Previous Close | 0.4 |
| Open | 0.39 |
| Day High | 0.42 |
| Day Low | 0.39 |
| 52-Week High | 2.04 |
| 52-Week Low | 0.17 |
| Volume | 837,552 |
| Average Volume | 8.17M |
| Market Cap | 61.59M |
| PE | -1.62 |
| EPS | -0.26 |
| Moving Average 50 Days | 0.33 |
| Moving Average 200 Days | 0.79 |
| Change | 0.02 |
If you invested $1000 in Biodesix, Inc. (BDSX) since IPO date, it would be worth $32.79 as of August 18, 2025 at a share price of $0.42. Whereas If you bought $1000 worth of Biodesix, Inc. (BDSX) shares 3 years ago, it would be worth $200 as of August 18, 2025 at a share price of $0.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 05, 2025 10:00 AM GMT
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside cha
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire Inc.
Jul 24, 2025 10:00 AM GMT
LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
GlobeNewswire Inc.
Jun 10, 2025 10:17 AM GMT
Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programsLOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic s